Levee Medical has shared an update. The company announced that Potomac Urology Center and Dr. Aseem Malhotra have enrolled their first patient in the ARID II IDE pivotal trial, becoming the 13th clinical site to enroll a patient. The ARID II study is designed to evaluate Levee Medical’s Voro® Urologic Scaffold and its impact on early and long-term continence outcomes following prostate surgery.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
For investors, the expansion of patient enrollment and the addition of another active site represent progress in the company’s clinical development timeline. Successful advancement of the ARID II pivotal trial is a key step toward generating the safety and efficacy data required for potential regulatory clearance and eventual commercialization of the Voro device. If trial results ultimately demonstrate meaningful improvements in post-prostatectomy continence, Levee Medical could strengthen its position in the urology and surgical devices market, addressing a significant quality-of-life issue for prostate surgery patients.
Continued trial enrollment also signals operational execution and growing clinician engagement with the technology, both of which may support future adoption if approved. However, the update does not provide efficacy or safety data at this stage, and the financial impact will depend on trial outcomes, regulatory pathways, reimbursement decisions, and competitive dynamics within the urologic devices segment.